Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Baclofen may be a useful therapy in GERD

Treating GERD patients with baclofen for 1 month reduces esophageal acid reflux and improves symptoms, claim researchers reporting to DDW 2002.

News image

fiogf49gjkf04

A team from Pescara, Italy, assessed the effects of 1-month treatment with baclofen, a gamma-aminobutyric acid (GABAB) agonist, in patients with gastroesophageal reflux disease (GERD).

They presented their findings at Digestive Diseases Week 2002, held this week in San Francisco, California, USA.

Previous studies have shown that short-term administration of baclofen, for 24 hours, reduces reflux episodes in GERD patients and in controls.

The researchers assessed its effect on 24-hour pH-metry and symptoms before and after the treatment.

A total of 14 GERD patients were included in the study.

At entry all patients underwent a 24-hour esophageal pH-metry.

In addition, they completed a questionnaire on various symptoms, including bitter taste, belching, fasting epigastric pain, post-prandial epigastric pain, nocturnal epigastric pain, heartburn, regurgitation, and dysphagia.

The intensity and frequency of each symptom were scored from 0 to 4.

Mean number of reflux episodes:
Before baclofen: 257
After treatment: 54
DDW

Patients were randomly assigned to receive baclofen (10 mg orally, four times daily [n = 10]) or placebo (n = 4).

The authors then re-evaluated 24-hour pH-metry and total symptoms score at the end of treatment.

In each recording, the pH was analyzed for total number of acid reflux and percentage of time with pH < 4 in the esophagus.

Two patients in the baclofen group dropped out during treatment due to nocturna dyspnea and slight hypotension.

The mean number of reflux episodes was significantly lower after treatment with baclofen (257 before baclofen, 54 after baclofen).

Furthermore, the percentage of time with pH < 4, was also significantly lower after treatment with baclofen (6% before baclofen, 3% after baclofen).

There was no difference in reflux episodes and in percentage of time with pH < 4 after treatment in the 4 patients treated with placebo.

The researchers found that the intensity and frequency of symptoms were both significantly improved after treatment with baclofen (mean total symptoms score: intensity 1.7 before baclofen, 0.4 after; frequency 2.2 before baclofen, 0.4 after).

However, there was no difference in intensity and frequency of the symptom score after treatment with placebo.

Dr Antonio Francesco Ciccaglione said on behalf of his colleagues, "Baclofen, given for 1 month, reduces esophageal acid reflux and significantly improves symptoms in patients with GERD.

"These results suggest that baclofen may be a useful therapy in GERD", he concluded.

DDW
21 May 2002

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us